Format

Send to

Choose Destination
J Cutan Med Surg. 2002 Nov-Dec;6(6):541-5. Epub 2002 Sep 12.

Long-term safety of spironolactone in acne: results of an 8-year followup study.

Author information

1
Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada. jc.shaw@utoronto.ca

Abstract

BACKGROUND:

Spironolactone has been used for over 20 years as an antiandrogen in the treatment of acne and hirsutism. No long-term studies of the safety of spironolactone used in this manner have been published. We present a study of the long-term safety and tolerance of spironolactone in 91 women with acne who were followed for up to 8 years.

METHODS:

A survey questionnaire was sent to 210 patients, and a comparison chart review of all patients to whom the survey was sent was made.

RESULTS:

Ninety-one completed surveys were analyzed, comprising 506 person-years of followup and 200 person-years of spironolactone exposure. Mean treatment length was 28.5 months (range = 0.5-122 months). During the 8-year followup period, there were no cases of serious illness attributable to spironolactone use. Side effects were present in 59% and resulted in cessation of the drug in 15%. Diuretic effect and menstrual irregularities were the most common adverse effects.

CONCLUSIONS:

After 200 person-years of exposure to spironolactone and 506 person-years of followup over 8 years, no serious illnesses thought to be attributed to spironolactone were reported. The long-term use of spironolactone in the treatment of acne in women appears to be safe. Side effects, however, are common, although not usually a cause for stopping the drug.

PMID:
12219252
DOI:
10.1177/120347540200600604
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center